Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exagen (XGN) Return on Capital Employed (2019 - 2025)

Historic Return on Capital Employed for Exagen (XGN) over the last 7 years, with Q3 2025 value amounting to 0.26%.

  • Exagen's Return on Capital Employed rose 1500.0% to 0.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.26%, marking a year-over-year increase of 1500.0%. This contributed to the annual value of 0.37% for FY2024, which is 200.0% up from last year.
  • Exagen's Return on Capital Employed amounted to 0.26% in Q3 2025, which was up 1500.0% from 0.36% recorded in Q2 2025.
  • Exagen's Return on Capital Employed's 5-year high stood at 0.14% during Q2 2021, with a 5-year trough of 0.61% in Q3 2023.
  • Over the past 5 years, Exagen's median Return on Capital Employed value was 0.4% (recorded in 2024), while the average stood at 0.38%.
  • In the last 5 years, Exagen's Return on Capital Employed tumbled by -3500bps in 2023 and then surged by 2100bps in 2024.
  • Exagen's Return on Capital Employed (Quarter) stood at 0.21% in 2021, then crashed by -164bps to 0.55% in 2022, then grew by 11bps to 0.49% in 2023, then increased by 8bps to 0.45% in 2024, then surged by 41bps to 0.26% in 2025.
  • Its Return on Capital Employed stands at 0.26% for Q3 2025, versus 0.36% for Q2 2025 and 0.49% for Q1 2025.